Background. A pacemaker system consists of one or two leads connected to a device that is implanted into a pocket formed just below the collarbone. This pocket is typically subcutaneous, that is, located just above the pectoral fascia. Even though the size of pacemakers has decreased markedly, complications due to superficial implants do occur. An alternative technique would be intramuscular placement of the pacemaker device, but there are no randomized controlled trials (RCTs) to support this approach, which is the rationale for the Placement Of Cardiac PacemaKEr Trial (POCKET). The aim is to study if intramuscular is superior to subcutaneous placement of a pacemaker pocket. Methods. In October 2016, we started to enroll 200 consecutive patients with an indication for bradycardia pacemaker implantation. Patients are randomized to random block sizes, stratified by age group (cut-off: 65 years) and sex, and then randomized to either subcutaneous or intramuscular implant. A concealed allocation procedure is employed, using sequentially numbered, sealed envelopes. Pocket site is blinded to the patient and in all subsequent care. The primary endpoint is patient overall satisfaction with the pocket location at 24 months as measured using a visual analog scale (VAS) 0-10. Secondary endpoints are: complications, patient-reported satisfaction at 1, 12, and 24 months (overall satisfaction, pain, discomfort, degree of unsightly appearance, movement problems, and sleep problems due to device). Conclusions. POCKET is a prospective interventional RCT designed to evaluate if intramuscular is superior to subcutaneous placement of a bradycardia pacemaker during a two-year follow-up.
Arrhythmia, Complication, Pacemaker, Pocket, Randomized controlled trial
Financial support: Region Gävleborg funded this research project.
Peter Magnusson Cardiology Research Unit Department of Medicine Karolinska Institutet Karolinska University Hospital/Solna SE-171 76 Stockholm, Sweden firstname.lastname@example.org
Share this Article
Related Content In Interventional Cardiology
The ACURATE neo™ and neo2™ Valve Systems
Heart International. 2021;15(1):Online ahead of journal publication
Transcatheter aortic valve replacement (TAVR) has seen worldwide explosive growth. The current USA guidelines no longer use risk in choosing between TAVR and surgical aortic valve replacement, and the European guidelines have extended the recommendation for TAVR to lower risk groups.1,2 This rapid expansion has been driven by data from randomized trials showing TAVR as […]
Foreword – Heart International. 2020;14(2):66
Welcome to the latest edition of Heart International. I would like to begin by paying tribute to all the victims of the coronavirus pandemic. I know of very few people who have not lost a family member, friend, colleague or a neighbour with COVID-19. Such deaths are not simply statistics, for behind each death is a […]
A Review of Bleeding Risk with Impella-supported High-risk Percutaneous Coronary Intervention
Heart International. 2020;14(2):92-99 DOI: https://doi.org/10.17925/HI.2020.14.2.92
Percutaneous coronary intervention (PCI) has evolved over recent years, with increasingly more complex, high-risk procedures being performed, including in patients with multivessel coronary artery disease with or without left main disease, often complicated by severe left ventricular (LV) dysfunction.1 In addition, decisions about coronary bypass surgery or PCI often focus not only on coronary anatomy, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!